Literature DB >> 18039192

Effect of biphasic insulin aspart 30 combined with metformin on glycaemic control in obese people with type 2 diabetes.

Belma Ascić-Buturović1.   

Abstract

Combination therapy consisting of biphasic insulin aspart 30 bid with metformin provide better glycaemic control in obese patients with diabetes mellitus type 2. In our study, patients who were treated with 2550 mg of metformin, administered in three daily doses had poor glycaemic control. Three months after switching from metformin therapy to treatment with biphasic insulin aspart 30 + metformin twice a day, glycaemic control improved with significant reduction in hemoglobin HbA1c, fasting blood glucose and postprandial blood glucose levels. Biphasic insulin aspart 30 in combination with metformin administered twice a day may be recommended as a starting insulin treatment in obese diabetic persons whose glycaemic control remained poor while on oral metformin therapy alone.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18039192      PMCID: PMC5728607          DOI: 10.17305/bjbms.2007.3023

Source DB:  PubMed          Journal:  Bosn J Basic Med Sci        ISSN: 1512-8601            Impact factor:   3.363


  6 in total

Review 1.  Early intensive insulin treatment for induction of long-term glycaemic control in type 2 diabetes.

Authors:  B Glaser; E Cerasi
Journal:  Diabetes Obes Metab       Date:  1999-03       Impact factor: 6.577

2.  Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.

Authors:  I M Stratton; A I Adler; H A Neil; D R Matthews; S E Manley; C A Cull; D Hadden; R C Turner; R R Holman
Journal:  BMJ       Date:  2000-08-12

3.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.

Authors: 
Journal:  BMJ       Date:  1998-09-12

4.  Hyperglycemia-induced beta-cell apoptosis in pancreatic islets of Psammomys obesus during development of diabetes.

Authors:  M Y Donath; D J Gross; E Cerasi; N Kaiser
Journal:  Diabetes       Date:  1999-04       Impact factor: 9.461

5.  Prolonged exposure of human pancreatic islets to high glucose concentrations in vitro impairs the beta-cell function.

Authors:  D L Eizirik; G S Korbutt; C Hellerström
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

6.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

  6 in total
  1 in total

Review 1.  Ten years of experience with biphasic insulin aspart 30: from drug development to the latest clinical findings.

Authors:  Andreas Liebl; Vinay Prusty; Paul Valensi; Ryuzo Kawamori; Jens Sandahl Christiansen; Andrew J Palmer; Per Balschmidt; Robert Ligthelm; Viswanathan Mohan
Journal:  Drugs       Date:  2012-07-30       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.